Feature | July 08, 2013 | Raissa Rocha

Integration, Reporting Among Key Areas for OIS

With Stage 2 meaningful use on their minds, hospitals and clinics are looking for software that will interface easily for users

Elekta Mosaiq Evaluate is a toolset that unites plan and dose review capabilities in a single software framework, the Mosaiq Oncology Information System (OIS).

Elekta Mosaiq Evaluate is a toolset that unites plan and dose review capabilities in a single software framework, the Mosaiq Oncology Information System (OIS).

With the sheer volume of patient information growing by the minute in the healthcare industry, it is important for providers to have an information system that not only captures and maintains data, but also performs its functions effectively and meaningfully. As the electronic health record (EHR) requirements for Stage 2 meaningful use (MU) continue to bear down on clinicians, vendors — especially in the field of oncology — will need to tweak and adjust to ensure their systems fulfill the needs of providers.

Integration is Key

Though the field is dominated by a few major players, the door has been opened for enterprise vendors in the oncology information system (OIS) market. “We see the large enterprise vendors moving into the oncology space,” says Monique Rasband, oncology research director at KLAS. She adds that with more hospitals and clinics looking to bring their systems together under one roof, “oncology has become a hot topic among CIOs and clinicians who are trying to find a balance between functionality and integration.”

And integration remains key for all OIS vendors, says Rasband. With such a specialized department, it is becoming more important for systems to be able to fit in with the rest of the hospital’s network. “Oncology is a difficult animal,” she says. “This is probably why there are so few true OIS vendors in the market. It is important for these systems to be able to interface with other departments as well as the core electronic medical record in the hospital.”

Room for Improvement

In the latest Best In KLAS report for software and services, three vendors — Elekta, IntrinsiQ and Varian — were ranked as meeting the minimum KLAS Konfidence level for the oncology software market segment. Elekta’s Mosaiq system took the top spot for 2012. Another recent KLAS report, “Oncology 2012: Pulling the Curtain Back,” surveyed OIS users and healthcare providers — from physicians to information technology (IT) directors and managers to executives — on the top vendors in the market. The report found that alerts and reporting were the areas oncology providers were least happy with overall, with participants expressing that vendors’ customized reports were not as user-friendly as needed, or were particularly difficult to use.

“Reporting is another area of focus and has been a pain point in the past,” says Rasband, who authored the KLAS report on oncology. “A system could have all of the functionality in the world, but if the user is not able to easily access the data stored, it does not do much good. This information needs to be easily accessible.”

A desire for improved patient portals was also expressed in the oncology survey. As Stage 2 MU rules stress the importance of keeping patients abreast of their health information, oncology providers are weighing portals as a factor in their purchasing decisions. Patient portals provide an avenue for patients to view their health information online, as well as download and transmit their records to other providers if needed. “This needs to be accessible and simple,” says Rasband of patient portals. “When we published our last report, there was a very low adoption rate of patient portals.” The latest report indicated only 30 percent of those surveyed had adopted a patient portal, with many still needing to make a decision.

She adds that providers are in need of oncology information systems that are ahead of the game with regard to MU, as eligible participants prepare to attest for Stage 2. Varian and Epic were named as vendors that could improve for MU, while Altos and BMSi were reported as the best partners for the financial incentive program. Here, Rasband again stresses the importance of integration for OIS, since Stage 2 MU also calls for computerized physician order entry (CPOE) of medication, laboratory and radiology orders, and hospitals and clinics will want systems that streamline the various workflows together.

Latest Features and Developments

Other features are also making their way into oncology software, as well as more capabilities to integrate OIS with radiation therapy systems. In January 2013 Elekta introduced Mosaiq Evaluate, a toolset that unites plan and dose review capabilities within the company’s OIS platform. The toolset, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA), streamlines planning activities inside the patient’s medical record, reducing wait times and delays as well as improving efficiency and productivity in the department. The goal of Mosaiq Evaluate is to integrate the treatment planning process with patient data and provide specific benefits for different members of the radiation oncology team, streamlining the radiotherapy workflow.

Similarly, the latest release of Varian’s Aria software, version 11, was designed to improve ease of use and interoperability with the company’s Eclipse treatment planning software. In April 2012 Varian announced a new strategic global partnership with Siemens Healthcare that includes the development of interfaces that will enable Varian’s Aria software to more easily connect with Siemens accelerators and imaging systems, giving providers more options for streamlining workflow and devising imaging and treatment solutions.

A Changing Landscape

With Stage 2 meaningful use rules bearing down and hospitals looking to integrate their information systems under one roof, there are many areas in the oncology software market for vendors to improve in. “The true blue OIS vendors are really being put to the test as they work fast and furiously to push the envelope on features and capabilities,” says Rasband.

“Traditionally, oncology was a group of physicians in a private practice who solely focused on cancer care. Now we are seeing these groups consolidated into either a larger multispecialty group or taken on by the hospital,” she adds. “The landscape is rapidly changing.” 

Related Content

User's of Varian's 360 Oncology platform can see all of their current patients and associated tasks at a glance when they log in

User's of Varian's 360 Oncology platform can see all of their current patients and associated tasks at a glance when they log in.

Feature | Oncology Information Management Systems (OIMS) | September 08, 2017 | By Jeff Zagoudis
Cancer is perhaps the most highly personal, complex disease in our world today.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Sponsored Content | Case Study | Radiation Therapy | June 08, 2017
Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than conventional...
pediatric imaging
News | Radiation Oncology | June 08, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that e
Overlay Init